Open in interactive viewer → charts, metric popovers & call review

VitalHub: The Margin Snap-Back Meets the Palantir Clause

Recurring revenue crossed 81% of the mix and adjusted EBITDA hit a two-year high — but a ~7% slice of ARR in the U.K. now hangs on an NHS decision management refuses to size.
VHI.TO · Earnings Call · 2026-11-13

The optics problem: flat headline, better business

On the surface, VitalHub's Q3 2026 looks like a stall: total revenue of $31.9 million arrived flat year-over-year. Look underneath and the mix has quietly improved. Recurring revenue — term license, maintenance and support — was $25.8 million, or 81% of the total, up from $23.6 million and 74% a year ago. The flat top line is an artifact of the two lumpy pieces: perpetual license revenue collapsed to $100,000 from $500,000, and services/hardware fell to $3.7 million from $5.5 million as the summer quarter came in light on revenue recognition. Management is adamant this is timing, not deterioration. “our backlog for our services revenue has never been stronger. It was just the case of getting it into the revenue recognition state, and that tends to be lumpy.” — Daniel Matlow, Chief Executive Officer · 2026-11-13 The payoff showed up on the bottom line: adjusted EBITDA of $8.6 million (27% of revenue, versus $7.2 million / 22% prior year) was the highest margin in the last two years, and net income swung to $2.6 million from a $900,000 loss. Nine-month operating cash flow of $23.9 million was up 69%, against a balance sheet holding $129 million of cash and short-term investments with no debt. Whatever the revenue optics say, the cash machine is running.

SHREWD: the recurring overhang with a hard deadline

The word dominating this quarter's keyword set is SHREWD scenario — VitalHub's U.K. business that sits inside the NHS's Federated Data Platform ecosystem, tied to Palantir. It is roughly 7–8% of ARR, or about $10 million in Dan Matlow's estimate, and the situation is fluid in the worst way: customers suspending, some un-suspending, renewals flipping by the week. When analysts pressed for the range of outcomes, Matlow declined to draw the map:

I'm reluctant to give out the exact numbers because they change literally by the week... if we didn't have the suspensions or the reversals on some of those SHREWD cuts, we would have been very close to our Rule of 40 base level.

Daniel Matlow, Chief Executive Officer · 2026-11-13
The genuinely new catalyst is a contractual clock. Matlow pointed to a break clause in the Palantir contract exercisable in February 2027: “They have a break clause in their contract for February of 2027 that they can exercise on the Palantir product.” — Daniel Matlow, Chief Executive Officer · 2026-11-13 That decision — extend, transition away, or muddle through — is the swing factor for whether VitalHub returns to Rule-of-40 economics in 2027. Crucially, this is not a new theme. The prior call (2026-08-07) was already deep in it, with Doug Taylor asking directly “with the impact of Schreud, some of the pause that you're talking about. Is that something that is reflected in the net ARR growth?” — Analyst Doug Taylor, Analyst · 2026-08-07 and Matlow conceding “we definitely took some AR reduction in the quarter with some of the Schreud work.” — Daniel Matlow, CEO · 2026-08-07 What has changed is the specificity: the ~7–8% ARR figure is now on the record, and the February 2027 deadline turns a vague "wait and see" into a dated event.

AI: four products and a $30–40 million TAM claim

Matlow spent his prepared remarks sketching an AI build-out that is now concrete enough to name: a transcription product in the TREAT suite, a protocoling product inside Novari, and two clinical decision support products — MedCurrent and MCAP — that lean on clinical guidelines to auto-surface recommendations against patient data. The most quotable number of the call was the addressable uplift: “by adding AI products into our installed base, there's probably about $30 million, $40 million of TAM just on top of that.” — Daniel Matlow, Chief Executive Officer · 2026-11-13 That is a big claim relative to a $293 million market cap, and it follows a theme management has been building for several quarters — the prior call described a home-built scribing solution expected to reach uptake in 2027. The difference now is that AI has shifted from R&D slide-ware to productized features with a named customer base and, per Matlow, a reframing of the whole company as an integrated platform with individual modules rather than a portfolio of point brands. That reframing is the quiet strategic pivot: sell the suite, not the SKU.

Capital allocation: the buyback that never came

With $129 million of cash and an NCIB on the books, investors had been primed for share repurchases — the prior call had Matlow floating that the board could "do both" buybacks and M&A. Through September, zero shares were bought. The reason is a familiar one from this management team: preserving dry powder for a deal it has chased for years. “we do think the company operationally is in a really strong position that it can absorb something of some larger size,” — Daniel Matlow, Chief Executive Officer · 2026-11-13 Matlow said — echoing the prior call's framing of targets "meaningfully larger than Novari." The Buddy Healthcare integration is still early, but Matlow flagged a natural cross-sell into Novari's surgical-referral relationships across roughly 40% of Canadian hospitals, a quiet signal that the referral business is the growth engine to watch.

The verdict

The market is being asked to pay for two things at once: a durable cash compounder (27% margins, $129 million net cash, 81% recurring mix) and a leveraged call option on the NHS resolving in VitalHub's favor by early 2027. The tension in this report is that the flat revenue headline and the SHREWD evasiveness read bearishly, while everything management actually controls — margins, cash conversion, product integration, M&A readiness — read bullishly. The mental health and Canadian provincial rollouts are making up ground, but the swing factor remains a bureaucratic decision in London that no amount of operational excellence can influence. Rule of 40 in 2027 is plausible; its probability is currently hostage to a February break clause.